Physician profile
Emilee Dodd
NPI 1538852116
$2,329.70
in general payments reported to CMS, 2019-2025
23 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $171 · 2024: $909 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $544.31 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $379.74 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $184.09 | 2023-2025 | |
| Lilly USA, LLC | $154.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $146.52 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $108.10 | 2024-2025 | Voquezna |
| Amgen INC. | $104.26 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $88.19 | 2024-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $75.29 | 2024-2025 | Auvelity |
| Abbott Laboratories | $66.67 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $61.51 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $48.68 | 2024-2025 | Spravato |
| Corcept Therapeutics | $48.10 | 2025 | Korlym |
| Dexcom, INC. | $44.45 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.11 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $36.85 | 2023-2024 | Quviviq |
| Lundbeck LLC | $35.82 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.60 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $31.78 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.14 | 2023-2025 | Xifaxan, Trulance |
| Eisai INC. | $24.57 | 2025 | |
| Boston Scientific Corporation | $19.30 | 2025 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $18.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilee Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.